Table 3.
Results of N-Staging according to [18F]FDG PET/CT, [68 Ga]FAPI-04 PET/CT and MR imaging
| Histo | [18F]FDG PET/CT | [68 Ga]FAPI-04 PET/CT | MRI | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pat # | LN (Mets/total) | TP | FP | TN | FN | Effect on N-Staging | TP | FP | TN | FN | Effect on N-Staging | TP | FP | TN | FN | Effect on N-Staging |
| 1 | 4 / 59 | 4 | 0 | 55 | 0 | → | 3 | 0 | 55 | 1 | → | 1 | 0 | 55 | 3 | ↓ |
| 2 | 3 / 50 | 3 | 1 | 46 | 0 | → | 3 | 0 | 47 | 0 | → | 3 | 2 | 45 | 0 | → |
| 3 | 0 / 36 | - | 0 | 36 | - | → | - | 0 | 36 | - | → | - | 0 | 36 | - | → |
| 4 | 1 / 53 | 0 | 1 | 51 | 1 | → * | 0 | 0 | 52 | 1 | ↓ | 0 | 1 | 51 | 1 | → * |
| 5 | 1 / 47 | 1 | 0 | 44 | 0 | → | 1 | 1 | 45 | 0 | → | 1 | 1 | 45 | 0 | ↑ |
| 6 | 0 / 23 | - | 1 | 22 | - | ↑ | - | 0 | 23 | - | → | - | 0 | 23 | - | → |
| 7 | 1 / 49 | 1 | 0 | 48 | 0 | → | 1 | 0 | 48 | - | → | 0 | 0 | 48 | 1 | ↓ |
| 8 | 4 / 46 | 3 | 0 | 42 | 1 | → | 3 | 0 | 42 | 1 | → | 2 | 0 | 42 | 2 | ↓ |
| 9 | 0 / 14 | - | 0 | 14 | - | → | - | 0 | 14 | - | → | - | 0 | 14 | - | → |
| 10 | 2 / 57 | 2 | 0 | 55 | 0 | → | 2 | 0 | 55 | 0 | → | 1 | 1 | 54 | 1 | → * |
| 16/434 | 14/16 | 3/418 | 413/418 | 2/16 | 1/10 | 13/16 | 1/418 | 417/418 | 3/16 | 1/10 | 8/16 | 5/418 | 413/418 | 8/16 | 5/10 | |
* unchanged, but due to false positive lymph node; ↑, overstated; → , unchanged; ↓, understated; FAPI, fibroblast activation protein inhibitor; FDG, fluorodesoxyglucose; FN, false negative; FP, false positive; Histo, histopathology; LN, lymph node(s); Mets, metastases; MRI, magnetic resonance imaging; Pat #, patient number; TN, true negative; Total, total number of resected lymph nodes; TP, true positive